Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588307837> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2588307837 endingPage "818" @default.
- W2588307837 startingPage "815" @default.
- W2588307837 abstract "Objective To observe and compare efficacy and safety of vinorelbine (NVB) plus ifosfamide (IFO) (NI regimen) and NVB plus cisplatin(DDP) (NP regimen) in treatment of metastatic breast cancer.Methods 82 cases of recurrent and metastatic breast cancer after the failure of treatment with anthracyclines and taxanes,40 cases were treated with NI regimen (NVB 25 mg/m2,day 1,day 8,IFO 1.2 g/m2,day 1,day 2,day 3),and the other 42 cases received NP regimen (NVB 25 mg/m2,day 1,day 8,DDP 25 mg/m2,day 1,day 2,day 3).Both groups were constituted of 21 days one cycle.After 2 cycles of chemotherapy,the response rate and side effects were evaluated.Results All 82 cases were evaluated for objective response.The total response rate of NI group and NP group were 52.50 ％ (21/40) and 57.14 ％ (24/42).There was no significiant difference (P ＞ 0.05).By analysis of the correlative factors,the total response rate in treatment of triple-negative breast cancer of NI group was 43.75 ％ (7/16),and that of NP group was 44.44 ％ (8/18).The two rates were also approximative (P ＞ 0.05).Main side effects were both bonemarrow suppression and gastrointestinal reaction.Bonemarrow suppression rate at grade Ⅲ-Ⅳ of NI group [57.5 ％ (23/40)] had no significant difference compared with that of NP group[57.14 ％ (24/42)] (P ＞ 0.05).But grade Ⅲ-Ⅳ gastrointestinal rate of NI group [7.50 ％ (3/40)] was significantly lower than that of NP group [26.19％(11/42)](P ＜ 0.05).Conclusion NI regimen in treatment of advanced breast cancer is effective,and it shows a similar response rate compared with NP regimen.Also it is effective for triple negeative breast cancers.The toxicity can be tolerated,and the gastrointestinal reaction rate of NI regimen is lower.NI regimen is a good choose in treatment of advanced breast cancer.Key words: Breast neoplasms; Drug therapy, combination; Advanced stage" @default.
- W2588307837 created "2017-02-24" @default.
- W2588307837 creator A5008809919 @default.
- W2588307837 creator A5034227844 @default.
- W2588307837 creator A5082978816 @default.
- W2588307837 date "2012-12-28" @default.
- W2588307837 modified "2023-09-26" @default.
- W2588307837 title "Clinical research of the combination of vinorelbine and ifosfamide in the treatment of advanced breast cancer resistant to anthracycline and taxane" @default.
- W2588307837 doi "https://doi.org/10.3760/cma.j.issn.1006-9801.2012.12.007" @default.
- W2588307837 hasPublicationYear "2012" @default.
- W2588307837 type Work @default.
- W2588307837 sameAs 2588307837 @default.
- W2588307837 citedByCount "0" @default.
- W2588307837 crossrefType "journal-article" @default.
- W2588307837 hasAuthorship W2588307837A5008809919 @default.
- W2588307837 hasAuthorship W2588307837A5034227844 @default.
- W2588307837 hasAuthorship W2588307837A5082978816 @default.
- W2588307837 hasConcept C121608353 @default.
- W2588307837 hasConcept C126322002 @default.
- W2588307837 hasConcept C126894567 @default.
- W2588307837 hasConcept C2776694085 @default.
- W2588307837 hasConcept C2776802502 @default.
- W2588307837 hasConcept C2777506904 @default.
- W2588307837 hasConcept C2777511904 @default.
- W2588307837 hasConcept C2778239845 @default.
- W2588307837 hasConcept C2780350996 @default.
- W2588307837 hasConcept C2781413609 @default.
- W2588307837 hasConcept C530470458 @default.
- W2588307837 hasConcept C71924100 @default.
- W2588307837 hasConcept C90924648 @default.
- W2588307837 hasConceptScore W2588307837C121608353 @default.
- W2588307837 hasConceptScore W2588307837C126322002 @default.
- W2588307837 hasConceptScore W2588307837C126894567 @default.
- W2588307837 hasConceptScore W2588307837C2776694085 @default.
- W2588307837 hasConceptScore W2588307837C2776802502 @default.
- W2588307837 hasConceptScore W2588307837C2777506904 @default.
- W2588307837 hasConceptScore W2588307837C2777511904 @default.
- W2588307837 hasConceptScore W2588307837C2778239845 @default.
- W2588307837 hasConceptScore W2588307837C2780350996 @default.
- W2588307837 hasConceptScore W2588307837C2781413609 @default.
- W2588307837 hasConceptScore W2588307837C530470458 @default.
- W2588307837 hasConceptScore W2588307837C71924100 @default.
- W2588307837 hasConceptScore W2588307837C90924648 @default.
- W2588307837 hasIssue "12" @default.
- W2588307837 hasLocation W25883078371 @default.
- W2588307837 hasOpenAccess W2588307837 @default.
- W2588307837 hasPrimaryLocation W25883078371 @default.
- W2588307837 hasVolume "24" @default.
- W2588307837 isParatext "false" @default.
- W2588307837 isRetracted "false" @default.
- W2588307837 magId "2588307837" @default.
- W2588307837 workType "article" @default.